SK76797A3 - Therapeutic preparation for inhalation containing parathyroid hormone, pth - Google Patents

Therapeutic preparation for inhalation containing parathyroid hormone, pth Download PDF

Info

Publication number: SK76797A3
Authority: SK; Slovakia
Prior art keywords: parathyroid hormone; particles; inhalation; pth; therapeutic
Prior art date: 1994-12-22

Application number

SK767-97A

Other languages

English (en)

Slovak (sk)

Inventor

Kjell Backstrom

Bjorn Wallmark

Original Assignee

Astra Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-22

Filing date

1995-12-08

Publication date

1998-02-04

1994-12-22 Priority claimed from SE9404449A external-priority patent/SE9404449D0/xx

1995-07-12 Priority claimed from SE9502576A external-priority patent/SE9502576D0/xx

1995-12-08 Application filed by Astra Ab filed Critical Astra Ab

1998-02-04 Publication of SK76797A3 publication Critical patent/SK76797A3/sk

Links

108090000445 Parathyroid hormone Proteins 0.000 title claims abstract description 70
230000001225 therapeutic effect Effects 0.000 title claims abstract description 32
102000003982 Parathyroid hormone Human genes 0.000 title claims abstract description 23
239000000199 parathyroid hormone Substances 0.000 title claims abstract description 23
229960001319 parathyroid hormone Drugs 0.000 title claims abstract description 23
238000002360 preparation method Methods 0.000 title claims abstract description 17
239000000203 mixture Substances 0.000 claims abstract description 57
239000000843 powder Substances 0.000 claims abstract description 35
239000002245 particle Substances 0.000 claims abstract description 33
150000001875 compounds Chemical class 0.000 claims abstract description 16
238000000034 method Methods 0.000 claims abstract description 14
239000000126 substance Substances 0.000 claims abstract description 10
208000001132 Osteoporosis Diseases 0.000 claims abstract description 8
238000010521 absorption reaction Methods 0.000 claims abstract description 8
230000004071 biological effect Effects 0.000 claims abstract description 8
239000003937 drug carrier Substances 0.000 claims abstract description 8
210000002345 respiratory system Anatomy 0.000 claims abstract description 8
239000011362 coarse particle Substances 0.000 claims abstract description 7
239000013543 active substance Substances 0.000 claims abstract 7
125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
102100036893 Parathyroid hormone Human genes 0.000 claims description 47
238000009472 formulation Methods 0.000 claims description 14
101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 claims description 12
101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 claims description 12
102000058004 human PTH Human genes 0.000 claims description 12
150000001413 amino acids Chemical class 0.000 claims description 11
229940112141 dry powder inhaler Drugs 0.000 claims description 7
GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
239000008101 lactose Substances 0.000 claims description 5
239000007787 solid Substances 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 4
238000001704 evaporation Methods 0.000 claims description 3
230000008020 evaporation Effects 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 2
150000004676 glycans Chemical class 0.000 claims description 2
229920005862 polyol Polymers 0.000 claims description 2
150000003077 polyols Chemical class 0.000 claims description 2
229920001282 polysaccharide Polymers 0.000 claims description 2
239000005017 polysaccharide Substances 0.000 claims description 2
150000005846 sugar alcohols Chemical class 0.000 claims description 2
238000009736 wetting Methods 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 claims 3
238000002156 mixing Methods 0.000 claims 2
238000000227 grinding Methods 0.000 claims 1
239000002904 solvent Substances 0.000 claims 1
230000002685 pulmonary effect Effects 0.000 abstract description 5
OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 9
239000000654 additive Substances 0.000 description 6
230000000694 effects Effects 0.000 description 6
241000282472 Canis lupus familiaris Species 0.000 description 5
210000000988 bone and bone Anatomy 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
230000000996 additive effect Effects 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
210000004898 n-terminal fragment Anatomy 0.000 description 4
230000011164 ossification Effects 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
230000002411 adverse Effects 0.000 description 3
239000000443 aerosol Substances 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
238000001035 drying Methods 0.000 description 3
239000000428 dust Substances 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
239000011164 primary particle Substances 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
239000001509 sodium citrate Substances 0.000 description 3
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
239000000243 solution Substances 0.000 description 3
BTJVOUQWFXABOI-IHRRRGAJSA-N Arg-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N BTJVOUQWFXABOI-IHRRRGAJSA-N 0.000 description 2
239000000853 adhesive Substances 0.000 description 2
230000001070 adhesive effect Effects 0.000 description 2
230000001195 anabolic effect Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000008021 deposition Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
210000000214 mouth Anatomy 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
210000000689 upper leg Anatomy 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
RVLOMLVNNBWRSR-KNIFDHDWSA-N (2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O RVLOMLVNNBWRSR-KNIFDHDWSA-N 0.000 description 1
MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 1
RWCLSUOSKWTXLA-FXQIFTODSA-N Arg-Asp-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O RWCLSUOSKWTXLA-FXQIFTODSA-N 0.000 description 1
LIVXPXUVXFRWNY-CIUDSAMLSA-N Asp-Lys-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O LIVXPXUVXFRWNY-CIUDSAMLSA-N 0.000 description 1
206010065687 Bone loss Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
ZAPFAWQHBOHWLL-GUBZILKMSA-N Glu-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)N ZAPFAWQHBOHWLL-GUBZILKMSA-N 0.000 description 1
HGJREIGJLUQBTJ-SZMVWBNQSA-N Glu-Trp-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(O)=O HGJREIGJLUQBTJ-SZMVWBNQSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
MOJKRXIRAZPZLW-WDSKDSINSA-N Gly-Glu-Ala Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O MOJKRXIRAZPZLW-WDSKDSINSA-N 0.000 description 1
241000282414 Homo sapiens Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
APFJUBGRZGMQFF-QWRGUYRKSA-N Leu-Gly-Lys Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN APFJUBGRZGMQFF-QWRGUYRKSA-N 0.000 description 1
POMXSEDNUXYPGK-IHRRRGAJSA-N Leu-Met-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N POMXSEDNUXYPGK-IHRRRGAJSA-N 0.000 description 1
DAYQSYGBCUKVKT-VOAKCMCISA-N Leu-Thr-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DAYQSYGBCUKVKT-VOAKCMCISA-N 0.000 description 1
IOQWIOPSKJOEKI-SRVKXCTJSA-N Lys-Ser-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IOQWIOPSKJOEKI-SRVKXCTJSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
BRGQQXQKPUCUJQ-KBIXCLLPSA-N Ser-Glu-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BRGQQXQKPUCUJQ-KBIXCLLPSA-N 0.000 description 1
NIOYDASGXWLHEZ-CIUDSAMLSA-N Ser-Met-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O NIOYDASGXWLHEZ-CIUDSAMLSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000001088 anti-asthma Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
239000000924 antiasthmatic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000009172 bursting Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000004955 epithelial membrane Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008103 glucose Substances 0.000 description 1
VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
108010050848 glycylleucine Proteins 0.000 description 1
108010025306 histidylleucine Proteins 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
239000005457 ice water Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003434 inspiratory effect Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
108010044348 lysyl-glutamyl-aspartic acid Proteins 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
239000000845 maltitol Substances 0.000 description 1
235000010449 maltitol Nutrition 0.000 description 1
229940035436 maltitol Drugs 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000009806 oophorectomy Methods 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
210000002997 osteoclast Anatomy 0.000 description 1
229940043200 pentothal Drugs 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000541 pulsatile effect Effects 0.000 description 1
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
238000012552 review Methods 0.000 description 1
238000006748 scratching Methods 0.000 description 1
230000002393 scratching effect Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical compound [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 description 1
239000011343 solid material Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Otolaryngology (AREA)
Pulmonology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK767-97A 1994-12-22 1995-12-08 Therapeutic preparation for inhalation containing parathyroid hormone, pth SK76797A3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
SE9404449A SE9404449D0 (sv)	1994-12-22	1994-12-22	Therapeutic preparations for inhalation
SE9502576A SE9502576D0 (sv)	1995-07-12	1995-07-12	Therapeutic preparations for inhalation II
PCT/SE1995/001475 WO1996019206A1 (en)	1994-12-22	1995-12-08	Therapeutic preparation for inhalation containing parathyroïd hormone, pth

Publications (1)

Publication Number	Publication Date
SK76797A3 true SK76797A3 (en)	1998-02-04

Family

ID=26662192

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK767-97A SK76797A3 (en)	1994-12-22	1995-12-08	Therapeutic preparation for inhalation containing parathyroid hormone, pth

Country Status (27)

Country	Link
US (2)	US6436902B1 (cs)
EP (2)	EP0806945B1 (cs)
JP (1)	JPH10511090A (cs)
KR (1)	KR100389080B1 (cs)
CN (1)	CN1170527C (cs)
AR (1)	AR001779A1 (cs)
AT (1)	ATE238043T1 (cs)
AU (1)	AU703532B2 (cs)
BR (1)	BR9510516A (cs)
CA (1)	CA2206657C (cs)
CZ (1)	CZ182297A3 (cs)
DE (1)	DE69530519T2 (cs)
DK (1)	DK0806945T3 (cs)
EE (1)	EE9700136A (cs)
ES (1)	ES2197212T3 (cs)
FI (1)	FI972652A (cs)
HU (1)	HU218940B (cs)
IL (1)	IL116492A (cs)
IS (1)	IS4502A (cs)
MX (1)	MX9704544A (cs)
NO (1)	NO320432B1 (cs)
NZ (1)	NZ297921A (cs)
PL (1)	PL321094A1 (cs)
PT (1)	PT806945E (cs)
SK (1)	SK76797A3 (cs)
TR (1)	TR199501635A1 (cs)
WO (1)	WO1996019206A1 (cs)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6632456B1 (en) *	1993-06-24	2003-10-14	Astrazeneca Ab	Compositions for inhalation
US6794357B1 (en) *	1993-06-24	2004-09-21	Astrazeneca Ab	Compositions for inhalation
CN100548277C (zh) *	1997-03-20	2009-10-14	先灵公司	粉末附聚物的制备方法
US6503537B2 (en)	1997-03-20	2003-01-07	Schering Corporation	Preparation of powder agglomerates
US6495167B2 (en)	1997-03-20	2002-12-17	Schering Corporation	Preparation of powder agglomerates
DZ2873A1 (fr) *	1998-08-19	2003-12-15	Lilly Co Eli	Procédé pour augmenter la dureté et la rigidité osseuse.
EP1123401A1 (en)	1998-10-22	2001-08-16	The General Hospital Corporation	BIOACTIVE PEPTIDES AND PEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHrP)
AU5523701A (en) *	2000-04-06	2001-10-23	Wayne P Franco	Methods of using growth factors for treating heart disease
US20040121003A1 (en) *	2002-12-19	2004-06-24	Acusphere, Inc.	Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20050106209A1 (en) *	2003-11-13	2005-05-19	Mahmoud Ameri	Composition and apparatus for transdermal delivery
US20070020299A1 (en)	2003-12-31	2007-01-25	Pipkin James D	Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) *	2003-12-31	2007-01-25	Pipkin James D	Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
CN1976679B (zh)	2003-12-31	2011-08-31	锡德克斯药物公司	含有磺基烷基醚环糊精以及皮质甾类的吸入制剂
AU2005212315A1 (en) *	2004-02-10	2005-08-25	Advanced Inhalation Research, Inc.	Particles for inhalation rapid release properties
EP1730751B1 (en) *	2004-03-12	2009-10-21	The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin	A magnetoresistive medium
EP2708225B1 (en)	2004-04-23	2018-12-26	CyDex Pharmaceuticals, Inc.	DPI Formulation Containing Sulfoalkyl Ether Cyclodextrin
US7629331B2 (en)	2005-10-26	2009-12-08	Cydex Pharmaceuticals, Inc.	Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
CA2628945A1 (en) *	2005-11-10	2007-05-24	Board Of Control Of Michigan Technological University	Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US20070160542A1 (en) *	2005-12-20	2007-07-12	Verus Pharmaceuticals, Inc.	Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070185066A1 (en) *	2005-12-20	2007-08-09	Verus Pharmaceuticals, Inc.	Systems and methods for the delivery of corticosteroids
US20070197486A1 (en) *	2005-12-20	2007-08-23	Verus Pharmaceuticals, Inc.	Methods and systems for the delivery of corticosteroids
US20070178049A1 (en) *	2005-12-20	2007-08-02	Verus Pharmaceuticals, Inc.	Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070249572A1 (en) *	2005-12-20	2007-10-25	Verus Pharmaceuticals, Inc.	Systems and methods for the delivery of corticosteroids
JP2009526858A (ja) *	2006-02-15	2009-07-23	ティカレーケメデルアーベー	コルチコステロイド溶液を製造する方法
KR101661730B1 (ko)	2007-08-01	2016-10-04	더 제너럴 하스피탈 코포레이션	Ｇ―단백질 결합 수용체를 이용한 스크리닝 방법 및 관련 조성물
JP2013512688A (ja)	2009-12-07	2013-04-18	ミシガンテクノロジカルユニバーシティ	クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
WO2011143406A2 (en)	2010-05-13	2011-11-17	The General Hospital Corporation	Parathyroid hormone analogs and uses thereof
WO2012130193A1 (en)	2011-03-31	2012-10-04	Zentiva, K.S.	Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
US10266228B2 (en)	2016-06-24	2019-04-23	Easy2.Company B.V.	Drive train for a treadle scooter
KR20220160676A (ko) *	2020-03-30	2022-12-06	쓰촨 루저우 부창 바이오-파마슈티컬 컴퍼니 리미티드	인간 부갑상선 호르몬(pth)의 제형 및 그 제조 방법

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE261096C (cs)
BE556587A (cs)	1957-01-31	1957-04-11
US2992645A (en)	1958-05-06	1961-07-18	Benger Lab Ltd	Disperser for powders
GB1144905A (en) *	1965-03-25	1969-03-12	Fisons Pharmaceuticals Ltd	Substituted bis-(2-carboxy-chromonyl-oxy) derivatives and preparation and pharmaceutical compositions thereof
GB1242211A (en)	1967-08-08	1971-08-11	Fisons Pharmaceuticals Ltd	Pharmaceutical composition
GB1520247A (en)	1974-08-10	1978-08-02	Fisons Ltd	Pelletised medicament formulations
GB1569611A (en)	1976-01-23	1980-06-18	Fisons Ltd	Pelletised or granular medicament formulation
DE2750090A1 (de) *	1976-11-19	1978-06-01	Sandoz Ag	Neue verabreichungsformen fuer organische verbindungen
SE7812207L (sv) *	1977-12-01	1979-06-02	Welsh Nat School Med	Apparat, forfarande och framstellda produkter for anvendning vid administration av antihistaminer
JPS6034925B2 (ja)	1979-07-31	1985-08-12	帝人株式会社	持続性鼻腔用製剤およびその製造法
US4900730A (en)	1981-01-14	1990-02-13	Toyo Jozo Co., Ltd.	Preparation which promotes the absorption of peptides
SE438261B (sv) *	1981-07-08	1985-04-15	Draco Ab	Anvendning i dosinhalator av ett perforerat membran
CY1492A (en) *	1981-07-08	1990-02-16	Draco Ab	Powder inhalator
US5260306A (en) *	1981-07-24	1993-11-09	Fisons Plc	Inhalation pharmaceuticals
JPS59163313A (ja)	1983-03-09	1984-09-14	Teijin Ltd	経鼻投与用ペプチドホルモン類組成物
US4548922A (en) *	1983-06-06	1985-10-22	Beth Israel Hospital	Drug administration
US4959358A (en) *	1983-06-06	1990-09-25	Beth Israel Hospital Assn.	Drug administration
US4746508A (en) *	1983-06-06	1988-05-24	Beth Israel Hospital Assn.	Drug administration
US4963367A (en)	1984-04-27	1990-10-16	Medaphore, Inc.	Drug delivery compositions and methods
US5288498A (en) *	1985-05-01	1994-02-22	University Of Utah Research Foundation	Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US4537772A (en) *	1984-05-02	1985-08-27	Merck & Co., Inc.	Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines
JPS61267528A (ja)	1984-11-26	1986-11-27	Yamanouchi Pharmaceut Co Ltd	吸収促進剤を含有するカルシトニン経鼻剤
SE448277B (sv) *	1985-04-12	1987-02-09	Draco Ab	Indikeringsanordning vid en doseringsanordning for lekemedel
US5122127A (en)	1985-05-01	1992-06-16	University Of Utah	Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
EP0223831B1 (en)	1985-05-22	1992-07-15	Liposome Technology, Inc.	Liposome inhalation method and system
US4731360A (en) *	1985-08-16	1988-03-15	Merck & Co., Inc.	Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
US4847298A (en)	1985-08-16	1989-07-11	Merck & Co., Inc.	Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
SE453566B (sv)	1986-03-07	1988-02-15	Draco Ab	Anordning vid pulverinhalatorer
JPS632932A (ja)	1986-06-23	1988-01-07	Teijin Ltd	経鼻投与用粉末状組成物
WO1988001165A1 (en)	1986-08-11	1988-02-25	Innovata Biomed Limited	Pharmaceutical formulations comprising microcapsules
US5179079A (en)	1986-12-16	1993-01-12	Novo Nordisk A/S	Nasal formulation and intranasal administration therewith
GB8712176D0 (en)	1987-05-22	1987-06-24	Cosmas Damian Ltd	Drug delivery system
US5059587A (en) *	1987-08-03	1991-10-22	Toyo Jozo Company, Ltd.	Physiologically active peptide composition for nasal administration
EP0312052B1 (en)	1987-10-15	1994-01-05	Syntex (U.S.A.) Inc.	Intranasal administration of polypeptides in powdered form
JPH01117825A (ja)	1987-10-28	1989-05-10	Sanwa Kagaku Kenkyusho Co Ltd	鼻くう、副鼻くう投与用製剤及びその使用方法並びにその形状及び使用器具
EP0360340A1 (en)	1988-09-19	1990-03-28	Akzo N.V.	Composition for nasal administration containing a peptide
US5997856A (en)	1988-10-05	1999-12-07	Chiron Corporation	Method and compositions for solubilization and stabilization of polypeptides, especially proteins
JPH02104531A (ja)	1988-10-14	1990-04-17	Toyo Jozo Co Ltd	経鼻投与用生理活性ペプチド組成物
US5006343A (en)	1988-12-29	1991-04-09	Benson Bradley J	Pulmonary administration of pharmaceutically active substances
US4994439A (en)	1989-01-19	1991-02-19	California Biotechnology Inc.	Transmembrane formulations for drug administration
US5011678A (en) *	1989-02-01	1991-04-30	California Biotechnology Inc.	Composition and method for administration of pharmaceutically active substances
WO1990009385A1 (en)	1989-02-17	1990-08-23	The Liposome Company, Inc.	Lipid excipient for nasal delivery and topical application
IT8920486A0 (it)	1989-05-12	1989-05-12	Isf Spa	Composizioni farmaceutiche.
US5176132A (en)	1989-05-31	1993-01-05	Fisons Plc	Medicament inhalation device and formulation
JP2642486B2 (ja)	1989-08-04	1997-08-20	田辺製薬株式会社	難溶性薬物の超微粒子化法
GB8921222D0 (en)	1989-09-20	1989-11-08	Riker Laboratories Inc	Medicinal aerosol formulations
US5707644A (en)	1989-11-04	1998-01-13	Danbiosyst Uk Limited	Small particle compositions for intranasal drug delivery
US5376386A (en) *	1990-01-24	1994-12-27	British Technology Group Limited	Aerosol carriers
GB9001635D0 (en) *	1990-01-24	1990-03-21	Ganderton David	Aerosol carriers
US5118494A (en)	1990-03-23	1992-06-02	Minnesota Mining And Manufacturing Company	Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
JPH05963A (ja)	1990-04-13	1993-01-08	Toray Ind Inc	ポリペプチド類組成物
US5192548A (en) *	1990-04-30	1993-03-09	Riker Laboratoires, Inc.	Device
EP0527940A1 (en)	1990-05-08	1993-02-24	Liposome Technology, Inc.	Direct spray-dried drug/lipid powder composition
JPH0441421A (ja)	1990-06-07	1992-02-12	Taisho Pharmaceut Co Ltd	肺吸収組成物
SE9002895D0 (sv)	1990-09-12	1990-09-12	Astra Ab	Inhalation devices for dispensing powders i
GB9020544D0 (en) *	1990-09-20	1990-10-31	Sandoz Ltd	Improvements in or relating to organic compounds
JPH04149126A (ja)	1990-10-09	1992-05-22	Mitsubishi Kasei Corp	経粘膜投与用医薬組成物
IL99699A (en) *	1990-10-10	2002-04-21	Autoimmune Inc	Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
DE4039656A1 (de) *	1990-12-12	1992-06-17	Bissendorf Peptide Gmbh	Arzneimittel, enthaltend das humane parathormon-fragment (1-37) in der form des amids oder ethylamids als aktiven wirkstoff
WO1992016192A1 (en)	1991-03-15	1992-10-01	Amgen Inc.	Pulmonary administration of granulocyte colony stimulating factor
US5320094A (en)	1992-01-10	1994-06-14	The Johns Hopkins University	Method of administering insulin
ATE146359T1 (de)	1992-01-21	1997-01-15	Stanford Res Inst Int	Verbessertes verfahren zur herstellung von mikronisierter polypeptidarzneimitteln
EP0566135A1 (en)	1992-04-17	1993-10-20	Takeda Chemical Industries, Ltd.	Transmucosal composition comprising a peptide and a cytidine derivative
US5376359A (en) *	1992-07-07	1994-12-27	Glaxo, Inc.	Method of stabilizing aerosol formulations
KR100291620B1 (ko) *	1992-09-29	2001-10-24	추후제출	부갑상선호르몬의활성단편의폐를통한전달방법
WO1994016756A1 (en)	1993-01-29	1994-08-04	Miris Medical Corporation	Intrapulmonary delivery of hormones
US5364838A (en)	1993-01-29	1994-11-15	Miris Medical Corporation	Method of administration of insulin
WO1994023772A2 (en)	1993-04-06	1994-10-27	Minnesota Mining And Manufacturing Company	Deagglomerators for dry powder inhalers
US5506203C1 (en)	1993-06-24	2001-02-06	Astra Ab	Systemic administration of a therapeutic preparation
IS1796B (is) *	1993-06-24	2001-12-31	Ab Astra	Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5747445A (en)	1993-06-24	1998-05-05	Astra Aktiebolag	Therapeutic preparation for inhalation
US5661130A (en)	1993-06-24	1997-08-26	The Uab Research Foundation	Absorption enhancers for drug administration
TW402506B (en)	1993-06-24	2000-08-21	Astra Ab	Therapeutic preparation for inhalation
US5349947A (en)	1993-07-15	1994-09-27	Newhouse Michael T	Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow
US5514670A (en)	1993-08-13	1996-05-07	Pharmos Corporation	Submicron emulsions for delivery of peptides
CZ295827B6 (cs)	1994-03-07	2005-11-16	Nektar Therapeutics	Způsob aerosolizace dávky inzulinu, inzulinový přípravek a jeho použití
US6051256A (en)	1994-03-07	2000-04-18	Inhale Therapeutic Systems	Dispersible macromolecule compositions and methods for their preparation and use
US5451569A (en)	1994-04-19	1995-09-19	Hong Kong University Of Science And Technology R & D Corporation Limited	Pulmonary drug delivery system
WO1997010850A1 (en)	1995-09-21	1997-03-27	Andaris Limited	Transcytosis vehicles and enhancers for drug delivery

1995
- 1995-12-08 AU AU43199/96A patent/AU703532B2/en not_active Ceased
- 1995-12-08 HU HU9800553A patent/HU218940B/hu not_active IP Right Cessation
- 1995-12-08 KR KR1019970704255A patent/KR100389080B1/ko not_active IP Right Cessation
- 1995-12-08 SK SK767-97A patent/SK76797A3/sk unknown
- 1995-12-08 AT AT95941953T patent/ATE238043T1/de active
- 1995-12-08 ES ES95941953T patent/ES2197212T3/es not_active Expired - Lifetime
- 1995-12-08 CN CNB951969544A patent/CN1170527C/zh not_active Expired - Fee Related
- 1995-12-08 PL PL95321094A patent/PL321094A1/xx unknown
- 1995-12-08 DE DE69530519T patent/DE69530519T2/de not_active Expired - Lifetime
- 1995-12-08 MX MX9704544A patent/MX9704544A/es unknown
- 1995-12-08 BR BR9510516A patent/BR9510516A/pt not_active Application Discontinuation
- 1995-12-08 CA CA002206657A patent/CA2206657C/en not_active Expired - Fee Related
- 1995-12-08 CZ CZ971822A patent/CZ182297A3/cs unknown
- 1995-12-08 JP JP8519713A patent/JPH10511090A/ja active Pending
- 1995-12-08 EE EE9700136A patent/EE9700136A/xx unknown
- 1995-12-08 DK DK95941953T patent/DK0806945T3/da active
- 1995-12-08 EP EP95941953A patent/EP0806945B1/en not_active Expired - Lifetime
- 1995-12-08 EP EP02025764A patent/EP1283035A3/en not_active Withdrawn
- 1995-12-08 PT PT95941953T patent/PT806945E/pt unknown
- 1995-12-08 WO PCT/SE1995/001475 patent/WO1996019206A1/en active IP Right Grant
- 1995-12-21 TR TR95/01635A patent/TR199501635A1/xx unknown
- 1995-12-21 IL IL11649295A patent/IL116492A/xx not_active IP Right Cessation
- 1995-12-21 AR AR33475995A patent/AR001779A1/es unknown
1997
- 1997-06-02 NZ NZ297921A patent/NZ297921A/en not_active IP Right Cessation
- 1997-06-09 IS IS4502A patent/IS4502A/is unknown
- 1997-06-12 NO NO19972715A patent/NO320432B1/no not_active IP Right Cessation
- 1997-06-19 FI FI972652A patent/FI972652A/fi unknown
1999
- 1999-08-26 US US09/383,590 patent/US6436902B1/en not_active Expired - Fee Related
2002
- 2002-08-19 US US10/224,522 patent/US20030064928A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN1170527C (zh)	2004-10-13
KR100389080B1 (ko)	2003-10-17
NO972715L (no)	1997-06-12
NO320432B1 (no)	2005-12-05
IL116492A0 (en)	1996-03-31
JPH10511090A (ja)	1998-10-27
WO1996019206A1 (en)	1996-06-27
CA2206657A1 (en)	1996-06-27
ES2197212T3 (es)	2004-01-01
DE69530519T2 (de)	2004-03-04
HU218940B (hu)	2001-01-29
PL321094A1 (en)	1997-11-24
MX9704544A (es)	1997-10-31
FI972652A0 (fi)	1997-06-19
AU4319996A (en)	1996-07-10
TR199501635A1 (tr)	1996-10-21
US6436902B1 (en)	2002-08-20
EP0806945A1 (en)	1997-11-19
IL116492A (en)	2000-08-13
DE69530519D1 (de)	2003-05-28
DK0806945T3 (da)	2003-08-04
EP0806945B1 (en)	2003-04-23
CA2206657C (en)	2009-05-19
ATE238043T1 (de)	2003-05-15
US20020115588A1 (en)	2002-08-22
AU703532B2 (en)	1999-03-25
NO972715D0 (no)	1997-06-12
HUT77738A (hu)	1998-07-28
PT806945E (pt)	2003-09-30
CN1170361A (zh)	1998-01-14
NZ297921A (en)	2001-05-25
AR001779A1 (es)	1997-12-10
US20030064928A1 (en)	2003-04-03
EE9700136A (et)	1997-12-15
BR9510516A (pt)	1998-07-07
CZ182297A3 (cs)	1998-01-14
EP1283035A2 (en)	2003-02-12
EP1283035A3 (en)	2003-03-19
IS4502A (is)	1997-06-09
FI972652A (fi)	1997-08-18

Publication	Publication Date	Title
CA2206657C (en)	2009-05-19	Therapeutic preparation for inhalation containing parathyroid hormone, pth
RU2142815C1 (ru)	1999-12-20	Способы пульсирующего системного введения активного фрагмента паратиреоидного гормона (ртн) и фармацевтические композиции, содержащие биологически активный n-концевой фрагмент паратиреоидного гормона (ртн)
KR100419037B1 (ko)	2004-06-12	폐를통한인슐린의전달방법및그조성물
CA2166109C (en)	2004-12-14	Compositions for inhalation
KR20010073033A (ko)	2001-07-31	인슐리노트로픽 펩티드의 투여 방법
EP0460064A1 (en)	1991-12-11	Therapeutic aerosol formulations
US20090203576A1 (en)	2009-08-13	Methods and compositons for pulmonary delivery of insulin
EP2036572A1 (en)	2009-03-18	Process for drying a protein, a protein particle and a pharmaceutical composition comprising the protein particle
RU2175556C2 (ru)	2001-11-10	Способы и композиции для легочной доставки инсулина
TW576750B (en)	2004-02-21	Pharmaceutical composition for respiratory/pulmonary delivery of insulin and preparation method thereof